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Central Message
Neoadjuvant CRT and MIE have become more
prevalent in practice for the treatment of esophageal
cancer. 3HMIE can be safely performed in patients
treated with not just induction chemotherapy but also
radiation with good outcomes.
Perspective
MIE is safe and feasible in patients after receiving
both neoadjuvant chemotherapy and radiation ther-
apy. This study describes the experience of a high-
volume center that has achieved low mortality and
acceptable morbidity in comparative cohorts of
patients who received neoadjuvant treatment and no
treatment before surgery. The perioperative and
survival outcomes presented are similar to or better
than those reported in the published literature on
esophagectomy after neoadjuvant therapy.Induction therapy followed by esophagectomy has become standard for
treatment of intermediate-stage esophageal cancer in many centers. Herein
we evaluate the feasibility and safety of the 3-hole minimally invasive
esophagectomy (3HMIE) approach in patients who received induction
radiation and chemotherapy. Between 2003 and 2012, the records of 119
consecutive patients with esophageal cancer who underwent 3HMIE were
reviewed for perioperative complications and long-term outcomes. Compar-
ison was made between procedures performed for patients receiving neo-
adjuvant chemoradiation and patients who were treated with only surgery. Of
them, 78 patients received neoadjuvant chemoradiation and 41 patients were
treated with only surgery. Tumor locations were upper (2), middle (16), distal
(64), and gastroesophageal junction (37). In all, 76 patients were at clinical
stage IIA or above at presentation. Increased requirement for blood replace-
ment in the induction therapy group was signiﬁcant compared with the
surgery-only group. Operative time, estimated blood loss, proximal and distal
margin lengths, and length of stay were not signiﬁcantly different between the
cohorts. There was a 30-day perioperative death (0.8%), and this patient was
from the surgery-only group. No conduit necrosis or need for diversion was
recorded. Overall, 5-year survival was 62% among the 107 patients with
early-stage esophageal cancer. 3HMIE is feasible with low mortality and
acceptable morbidity even in patients with locally advanced esophageal
cancer who received neoadjuvant radiochemotherapy. Overall perioperative
and survival outcomes are similar to or better than those reported in the
published literature on esophagectomy after induction therapy.
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esophageal cancerINTRODUCTION
During the past 2 decades there has been an
increasing incidence of esophageal cancer in the
western world, thought to be related to the corre-
sponding increase in prevalence of Gastroesophageal
Reﬂux Disease, Barrett's esophagus, and obesity—all
risk factors for esophageal adenocarcinoma.1-3 The
increasing incidence of adenocarcinoma affecting
mostly the distal esophagus and the gastroesopha-
geal junction has made esophageal cancer the eighth
most common malignancy in the United States.
Surgical resection remains the gold standard treat-
ment of early and locoregionally advanced, non-
metastatic, middle, and distal esophageal cancer.
Multiple surgical approaches have been used to
accomplish esophagectomy. The differences among
them relate to the techniques of approach to the
thoracic esophagus, the extent of resection and
lymphadenectomy, and the site of the anastomosis.
Regardless of the approach used, esophagectomy
continues to be a relatively high-risk and complex
operation, particularly in the postchemoradiation
(CRT) setting. Pulmonary complications, in partic-
ular, remain high, increasing the postoperative
mortality rates.4,5
General advances in laparoscopic and thoraco-
scopic skills as well as innovative tools prompted
some surgeons to perform minimally invasive esoph-
agectomy (MIE). Various operations have been
performed using the minimally invasive approach,
such as Ivor Lewis, transhiatal, and the 3-incision
esophagectomy.4,6-10 Since the initial reports by
Luketich et al,12,11 several other clinical series have
shown beneﬁcial results of MIE, claiming decreased
postoperative complications.7,13 However, most of
the initial cases have been early-stage cancers, high-
grade dysplasia, or patients undergoing neoadjuvant
chemotherapy alone. Only a few groups have used
this approach for the more locally advanced esoph-
ageal malignancies, treated before surgery with neo-
adjuvant CRT combination therapy,14,15 which has
been thought to be associated with higher rates of
perioperative complications.14,15
To address the paucity of published large series of
minimally invasive “3-hole esophagectomy” in the
setting after neoadjuvant CRT therapy, we focus
herein on this speciﬁc group. The aim of this study
was to demonstrate the feasibility of performing a
MIE in patients who have been treated with neo-
adjuvant radiation as other published series have
focused on patients treated with only neoadjuvant206 Seminchemotherapy. We present our technique, which is a
slight modiﬁcation of published ones, as well as the
operative, oncologic, short, and long-term results
and advantages of the MIE approach in this setting.METHODS
Patients and Data
As of 2005, a prospective database of all esoph-
agectomy cases performed at the Division of Thora-
cic Surgery at our institution has been maintained. In
addition, the entire retrospective data set of all
esophageal surgeries at our institution since 1988
was linked with the prospective database with
institutional review board approval. All patients
who underwent thoracoscopic and laparoscopic
minimally invasive esophagectomy (3HMIE) from
May 1, 2003 until June 30, 2012 were included this
study. Each patient's medical record was reviewed
for demographic and clinical data. Operative param-
eters included estimated blood loss (EBL), procedure
duration, intraoperative complications, and opera-
tive technique. The records were also assessed for
perioperative and pathologic data including extuba-
tion time, intensive care unit stay, transfusion needs,
length of hospital stay, postoperative complications,
30- and 90-day postsurgery mortality, histology,
pathologic staging, number of lymph nodes resected,
and number of involved lymph nodes. Patients were
staged according to the American Joint Committee
on Cancer classiﬁcation, seventh edition. The cohort
was then divided into 2 groups: patients who
received neoadjuvant CRT and the patients who
had surgery alone.
Fisher's exact and Wilcoxon rank-sum tests were
used to compare the 2 groups to evaluate any
differences in the preoperative characteristics as well
as intraoperative and perioperative outcomes,
depending on whether the data are categorical or
continuous. The 30-day and 90-day mortalities are
deﬁned, respectively, as death during the ﬁrst 30 and
90 days following the date of surgery. Follow-up
duration was deﬁned from the date of surgery until
the date of death or last documented follow-up; the
cutoff date for follow-up was August 13, 2013.
Overall survival was estimated by the Kaplan-Meier
method, with censoring of patients who have not
died. Median follow-up was reposted among all
patients still alive. The difference between stage
groups was assessed by the log-rank. All P values
are based on a 2-sided hypothesis. Statistical analysisars in Thoracic and Cardiovascular Surgery  Volume 27, Number 2
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Cary, NC).Patient Preoperative Evaluation
All patients underwent preoperative staging and
evaluation with upper endoscopy and biopsy, endo-
scopic ultrasound, chest and abdominal computed
tomography, and positron emission tomography.
Patients with early cancer were referred directly to
surgery, whereas most patients with locally advanced
tumors deﬁned as T2 and up, or N1 and up, under-
went preoperative neoadjuvant CRT. Patients who
received preoperative CRT were operated approxi-
mately 4-6 weeks after induction therapy completion.Surgical Technique
A 10-minute video of this approach, is available
through the AATS learning center (http://webcast.
aats.org/2013/Learning-Center.php).16,17
The 3HMIE technique used in our study is a
speciﬁc approach previously described by our insti-
tution. See operative technique described in supple-
mental appendix online.
RESULTS
Study Cohort
From May 2003 through June 2012, 838 patients
underwent esophagectomy, 485 open approach, 153
hybrid minimally invasive technique (thoracoscopy
and laparotomy or thoracotomy and laparoscopy),
and 200 MIE. There were 77 Ivor Lewis and 123
3HMIE and this latter group constitutes the core
clinical cohort described herein.Patient and Disease Characteristics
In all, 78 (63%) patients received neoadjuvant
CRT followed by surgery, whereas 45 patients (37%)
were treated with surgery alone (Table 1). The
surgery-only group included 2 benign pathologies
(stricture and achalasia) and 1 patient with Barrett's
esophagus who had intractable pain and reﬂux
symptoms as well as a patient with melanoma. Their
data are not included in the analysis of the surgery-
alone group, which is focused on those 41 patients
with primary esophageal tumors that could have
been potential candidates for neoadjuvant CRT. The
induction chemotherapy was platinum based with
either paclitaxel, irinotecan, or 5-ﬂuorouracil. The
induction radiotherapy median dose was 50.4 Gy.
The usual indication for induction CRT was stage
T2N0M0 or greater. There were a few patients with
IIA or IIB esophageal cancer who did not receive
neoadjuvant therapy before surgery based onic and Cardiovascular Surgery  Volume 27, Numbesurgeon's or patient's choice. Although there was a
statistically signiﬁcant difference in the clinical stage
distribution between the 2 groups, the groups were
comparable in most other parameters. In both
groups, most of the patients were men, and the
median age at operation was 63 years. The histo-
logical diagnosis was malignant or premalignant
primary esophageal tumors in both groups. The 2 groups
displayed adenocarcinoma histology predominance,
62 (79%) in the neoadjuvant group and 19 (46%) in
the surgery-only group. There was a higher inci-
dence of squamous cell carcinoma in the neoadju-
vant group (N ¼ 15, 19%, vs N ¼ 2, 5%, in the
surgery-only group). The surgery-only group
included 20 (49%) cases of high-grade dyplasia.
Most of the tumors in both groups, 65 (83%) in the
neoadjuvant group and 36 (88%) in the surgery-only
group, were located in the distal esophagus and
gastroesophageal junction.
The preoperative body mass index was signiﬁ-
cantly higher in the surgery-only group compared
with the neoadjuvant group (body mass index
Z30: 42% vs 19%, P ¼ 0.002). In the neoadjuvant
group, 28 (36%) patients underwent pretreatment
staging laparoscopy and jejunal feeding tube place-
ment for tube feeds during the CRT therapy period.
Only 1 patient (2%) in the surgery-only group
presented with malnutrition or dysphagia that
required tube feeding before the operation. The
preoperative albumin level was lower in the neo-
adjuvant group compared with the surgery-only
group (median ¼ 4.0, range: 2.7-4.9 vs 4.3, range:
2.3-4.9, P o 0.001). The median preoperative
hematocrit (HCT) was lower in the neoadjuvant
group compared with the surgery-only group:
median 35 (range: 29-45) vs 41 (range: 29-48),
P o 0.001. The incidence of preoperative comor-
bidities was similar between the 2 groups, 52 (67%)
vs 27 (66%). The main comorbidities were noted to
be cardiovascular. Most of the patients had prior
surgery, speciﬁcally abdominal surgery, which is a
risk factor for conversion to open surgery owing to
potential adhesions that could have led to other
complications during the more complicated dissec-
tion. The American Society of Anesthesiology classi-
ﬁcation score for the 2 groups was comparable.Technical Complications and Operative
Results
There were no signiﬁcant differences between the 2
groups in terms of operative duration, EBL, time to
extubation, and length of hospital and intensive care
unit stay (Table 2). The median operative time was
386minutes (238-653) in the neoadjuvant group andr 2 207
Table 1. Demographics of Patients (N ¼ 119), (2003-2012)
Neoadjuvant Treated
(N ¼ 78)
No Treatment
(N ¼ 41)
P value
Gender
Males 58 (74%) 34 (83%)
Females 20 (26%) 7 (17%) 0.360
Age at surgery (years)
Median (range) 63 (33-83) 63 (48-81) 0.798
Histology
Adenocarcinoma 62 (79%) 19 (46%)
Squamous cell carcinoma 15 (19%) 2 (4.9%)
High-grade dysplasia 0 (0.0%) 20 (49%)
Neuroendocrine tumor 1 (1.3%) 0 (0.0%) o0.001
Location
Proximal 1 (1.3%) 1 (2.4%)
Middle 12 (15%) 4 (9.8%)
Distal 42 (54%) 22 (54%)
Gastroesophageal junction 23 (29%) 14 (34%) 0.780
Body mass index
Z30 15 (19%) 19 (46%) 0.002
o30 63 (81%) 21 (51%)
Unknown 0 1 (2.4%)
Preoperative feeding tube 28 (36%) 1 (2.4%) o0.001
Preoperative comorbidities 52 (67%) 27 (66%) 1.000
Chronic obstructive pulmonary disorder 7 (9.0%) 3 (7.3%) 1.000
Cerebrovascular accident 0 (0.0%) 0 (0.0%)
Chronic renal insufﬁciency 1 (1.3%) 1 (2.4%) 1.000
Diabetes 14 (18%) 8 (20.0%) 0.810
Hypertension 44 (56%) 22 (54%) 0.847
Coronary artery disease 11 (14%) 4 (9.8%) 0.574
Peripheral vascular disease 1 (1.3%) 0 (0.0%) 1.000
Prior abdominal surgery 44 (56%) 21 (5%) 0.699
Prior thoracic surgery 7 (9.0%) 1 (42.4%) 0.260
Preoperative hematocrit
Median (range)
35.4 (29.3–45.2) 41.4 (28.7–48.3) 0.001
Preoperative albumin*
Median (range)
4.0 (2.7–4.9) 4.3 (2.3–4.9) 0.001
American Society of Anesthesiology classiﬁcation status
1 1 (1.3%) 0
2 30 (38%) 17 (41%)
3 45 (58%) 22 (54%)
Unknown 2 (2.6%) 2 (4.9%) 0.895
Charlson comorbidity score
0 0 2 (4.9%)
1 1 (1.3%) 2 (4.9%)
2 33 (42%) 17 (41%)
Z3 44 (56%) 20 (49%) 0.136
Clinical staging
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Table 1. Continued
Neoadjuvant Treated
(N ¼ 78)
No Treatment
(N ¼ 41)
P value
0 (Tis) 0 (0.0%) 20 (44%) o0.001
1A 0 (0.0%) 8 (20%)
1B 9 (12%) 6 (15%)
2A 8 (10%) 1 (2.4%)
2B 23 (29%) 6 (15%)
3A 26 (33%) 0 (0.0%)
3B 8 (10%) 0 (0.0%)
3C 2 (2.6%) 0 (0.0%)
4 2 (2.6%) 0 (0.0%)
Neoadjuvant radiation dose (Gray)† Median (range) 50.4 (41.4–59.4) N/A
*Albumin data were not available for 2 patients.
†Data not available for 15 patients who received neoadjuvant radiation.
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The initially long operating times were attributable to
the learning curves. A signiﬁcantly higher proportion
of patients in the neoadjuvant group were transfused,
N ¼ 50 (64%), compared with the surgery-only
group, N ¼ 14 (34%), P ¼ 0.002.
There was 1 patient in the neoadjuvant group with
an intraoperative complication, whereas none
occurred in the surgery-only group. A patient had
a small bowel injury mandating bowel resection.
A transcervical gastric tube was inserted in most
patients at a similar rate (N ¼ 54, 69% in the
neoadjuvant group and N ¼ 23, 56% in the surgery-
only group) with the rest having a transnasal gastric
tube. Pyloroplasty or pyloromyotomy was per-
formed in a similar minority of patients in both
groups. These 2 technical steps in the surgery were
based on the surgeon's preference.Pathology Results
A patient in the surgery-only group was found on
pathological analysis to have low-grade dysplasia and
no evidence of high-grade dysplasia or invasive
adenocarcinoma. R0 resection was achieved in 72
(92%) patients in the neoadjuvant group, and in 41
(100%) patients in the surgery-only group. R1
resection witho0.1 mm positive margins was noted
in 6 cases in the neoadjuvant group, all radial. The
distributions of proximal and distal margins were
similar between the neoadjuvant and the surgery-only
groups: medians of proximal 8.2 and 8.9 cm, and distal
7.0 and 6.1 cm, respectively. No signiﬁcant difference
was found in the number of lymph nodes dissected,
with a median 16 lymph nodes (range: 3-35) in the
induction CRT group and 17 (range: 1-39) lymph
nodes in the surgery-only group. Complete responseic and Cardiovascular Surgery  Volume 27, Numbewas observed in 27 (35%) patients who received CRT,
and partial response in 45 (58%) patients.Postoperative Complications
There were no signiﬁcant differences in the 30-day
postoperative complication rates between the 2
groups (Table 3). The CRT group had a combined
major and minor complication rate of 78% (N ¼ 61)
vs 68% (N ¼ 28) in the surgery-only group. Most
complications were minor, and were mainly pulmo-
nary, cardiac, and wound infections. All the cardiac
complications were related to arrhythmias. None of
the patients developed myocardial infarction. Most
of the pulmonary complications were pneumonia
requiring antibiotic treatment, pleural effusion not
requiring aspiration or drainage, and mild temporary
asymptomatic aspiration diagnosed on a contrast
swallow done routinely on postoperative day 7.
Although there was no signiﬁcant difference in the
incidence of wound infection at the neck incision
between the patients who underwent 3-hole esoph-
agectomy after neoadjuvant treatment and those who
had only surgery, there was a minimally higher
incidence of infection with the placement of a
transcervical gastric tube. A transcervical gastric tube
was placed instead of a nasogastric tube to decom-
press the neoesophagus after esophagectomy for
improved patient comfort and mobility,18 but this
practice was aborted.
There were no differences between the neoadju-
vant group and the surgery-only group when com-
paring the incidences of anastomotic leak (N ¼ 8,
10% vs N ¼ 3, 7%), anastomotic stricture requiring
early dilation (N¼ 7, 9% vs N¼ 4, 10%), vocal cord
injury (N ¼ 4, 5% vs N ¼ 2, 5%), and chylothorax
(N ¼ 5, 6% vs N ¼ 2, 5%), respectively. Anr 2 209
Table 2. Operative Results
Neoadjuvant Treated
(N ¼ 78)
No Treatment
(N ¼ 41)
P value
Operative time (min)
Median (range) 386 (238-653) 425 (236-716) 0.123
Estimated blood loss (cc)*
Median (range) 300 (100-1000) 400 (100-1000) 0.675
Number of nodes resected
Median (range) 16 (3-35) 17 (1-39) 0.471
Margin status
Negative margin 72 (92%) 41 (100%)
Positive margin 6 (7.7%) 0 0.092
(Radial) (6)
Margins (cm)†
Median (range)
Proximal 8.2 (0.1-18.0) 8.9 (1.4-16.0) 0.793
Distal 7.0 (0.3-18.0) 6.1 (3.5-15.5) 0.899
Radial 0.4 (0.1-1.5) 0.6 (0.1-2.0) 0.208
Neck gastric tube 54 (69%) 23 (56%) 0.164
Pyloroplasty or pyloromyotomy 11 (14%) 11 (27%) 0.134
Intraoperative complications 1 (1.3%) 0 1.000
Small bowel enterotomies (resected) 1 0
Hospital stay (days)
Median (range) 12 (8-49) 11 (1-77) 0.373
Number of patients who received packed red blood cells
(% of each cohort)
50 (64%) 14 (34%) 0.002
Median number of packed red blood cells administered per
hospitalization (units)
1 (0-6) 0 (0-49) 0.020
For those who received blood 2 (1-6) 2 (1-49) 0.138
Intensive care unit stay (days)‡
Median (range) 4 (2-49) 4 (1-54) 0.430
Time to extubation (postoperative day)‡,§
Median (range) 1 (0-11) 1 (0-14) 0.753
Pathologic staging
0 (pT0N0M0) N/A 1 (2.4%)
0 (pTisN0M0) N/A 14 (34%)
0 (ypT0N0M0) 25 (32%) N/A
0 (ypTisN0M0) 0 (0.0%) N/A
1A 10 (13%) 14 (34%)
1B 14 (18%) 6 (15%)
2A 5 (6.4%) 1 (2.4%)
2B 14 (18%) 2 (4.9%)
3A 2 (2.6%) 1 (2.4%)
3B 4 (5.1%) 1 (2.4%)
3C 1 (1.3%) 1 (2.4%)
4 2 (2.6%) 0 (0.0%)
T0N1M0 1 (1.3%) 0 (0.0%) o0.001
*Blood loss data were not available for 5 patients.
†Proximal and distal measurements were available for 66 patients; radial measurements were available for 53 patients.
‡Intensive care unit stay data were not available for 5 patients.
§Extubation data were not available for 5 patients.
THE 3-HOLE MINIMALLY INVASIVE ESOPHAGECTOMYesophagram to assess for anastomotic and conduit
leaks is routinely performed 7 days after surgery.
Anastomotic and conduit leaks not contained on
imaging were treated with surgical exploration and
drain placement. A patient in the surgery-only group210 Seminalso required an endoscopically placed stent for leak
treatment.
The 30-day mortality for the entire cohort was
0.8%. The single case of perioperative death was due
to a transfusion reaction on the ﬁrst day afterars in Thoracic and Cardiovascular Surgery  Volume 27, Number 2
Table 3. The 30-Day Postoperative Complications
Neoadjuvant
Treated
(N = 78)
No
Treatment
(N = 41)
P
Value
Total number of patients with complications 61 (78%) 28 (68%) 0.270
Pulmonary 20 (26%) 9 (22%) 0.823
Pneumonia 7 (9.0%) 4 (9.8%)
Empyema (decorticated) 1 (1.3%) 0 (0.0%)
Prolonged ventilation (need for ventilation greater than 7 days) 4 (5.1%) 2 (4.9%)
Pulmonary embolism 2 (2.6%) 1 (2.4%)
Recurrent aspiration 7 (9.0%) 2 (4.9%)
Pleural effusion requiring chest tube 9 (12%) 2 (4.9%)
(Required surgical drainage/pleurodesis) (0 (0.0%)) (1 (2.4%))
Cardiac 23 (29%) 10 (24%) 0.668
Atrial arrhythmias 23 (29%) 10 (24%)
Gastrointestinal 7 (9.0%) 4 (9.8%) 1.000
Ileus 7 (9.0%) 3 (7.3%)
Colitis 0 (0.0%) 2 (4.9%)
(Required colectomy) (0 (0.0%)) (1 (2.4%))
Vocal cord paralysis or paresis 4 (5.1%) 2 (4.9%) 1.000
(Required medialization) (3 (3.8%)) (2 (4.9%))
Deep vein thrombosis 1 (1.3%) 3 (7.3%) 0.117
Bleeding 1 (1.3%) 3 (7.3%) 0.273
Hemothorax (required thoracoscopy and chest tube
placement)
0 (0.0%) 1 (2.4%)
Rectus sheath hematoma 0 (0.0%) 1 (2.4%)
Perisplenic hematoma 1 (1.3%) 0 (0.0%)
Chylothorax 5 (6.4%) 2 (4.9%) 1.000
(Required interventional radiology) (4 (5.1%)) (0 (0.0%))
(Required surgical intervention) (1 (1.3%)) (2 (4.9%))
Wound infection 18 (23%) 9 (22%) 1.000
Neck 14 (18%) 6 (15%)
(With transcervical gastric tube) (11 (14%)) (4 (9.8%))
Abdomen 4 (5.1%) 3 (7.3%)
Anastomotic and conduit complications 14 (18%) 6 (15%) 0.798
Stricture requiring dilation 7 (9.0%) 4 (9.8%)
Leaks [anastomosis and conduit] 8 (10%) 3 (7.3%)
(Required surgical intervention) (2 (2.6%)) (1 (2.4%))
Bronchoesophageal ﬁstula 1 (1.3%) 0 (0.0%)
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90-day mortality was 3% for the whole cohort.
Additional 2 deaths included a patient who had
postoperative acute (superimposed on chronic) renal
failure and cardiac arrest, was discharged to a
rehabilitation center on postoperative day 77, and
was reported to die 4 days after his discharge. The
other patient was discharged to a rehabilitation
facility after a complicated postoperative course,
with delirium and aspiration. He died on
postoperative day 55. All 3 causes of death were
related to postoperative complications. Another
patient died on postoperative day 75 due to stage 4
cancer with pulmonary metastases discovered at
surgery.ic and Cardiovascular Surgery  Volume 27, NumbeThe surgery-only group has slightly longer follow-
up than the neoadjuvant group does. The median
follow-up was 32 (9-77) months in the neoadjuvant
group, and 37 (12-123) months in the surgery-only
group among all patients still alive at the last follow-
up. (Supplementary Table S4)
The 5-year survival for the entire cohort with
early-stage esophageal cancer is 62% (Fig. 1A), and
the induction therapy group has a 5 years survival
of 49% (Fig. 1). Figure 2A demonstrates the overall
survival by pathological stage in the induction
therapy group. The 5-year survival in this early-
stage group was found to be 50% for stage 0, 76%
for stage I, and 22% for stage II, where stage
0 represents complete response of previouslyr 2 211
Figure 1. (A) Overall survival for 107 patients with cancer of pathologic stages 0-2. (central picture). (B) Overall
survival for 69 patients with cancer of pathologic stages 0-2 (neoadjuvant group).
THE 3-HOLE MINIMALLY INVASIVE ESOPHAGECTOMYmore advanced cancer (P ¼ 0.119). Figure 2B
demonstrates the overall survival of early-stage
patients per pathologic disease stage in the surgery-
alone groups: Stage 0 82%, stage I 82% (P ¼ 0.813);
and stage II survival is not estimated as it is based on
only 3 patients. The median survival of early-stage
patients for the neoadjuvant treated group was 51
months and was not reached yet for the untreated
cohort.Figure 2. (A) Overall survival for patients with early-stage
(B) Overall survival for patients with early-stage cancer
212 SeminDISCUSSION
This study summarizes the operative and post-
operative results of 119 patients with primary
esophageal malignancy who underwent a 3HMIE
in a single institution over a period of 10 years and
compares these results between patients who
received induction neoadjuvant CRT and patients
who had surgery alone. There were no signiﬁcant
differences between these 2 cohorts in terms ofcancer—by pathologic stage in neoadjuvant group.
in surgery-only group—by pathological stage.
ars in Thoracic and Cardiovascular Surgery  Volume 27, Number 2
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that 3HMIE is a feasible and safe approach even in
patients who receive neoadjuvant CRT.
Up until several years ago, esophagectomy was
considered to be a high-risk procedure when per-
formed after induction CRT therapy. The presumed
high morbidity of esophageal surgery after induction
therapy, especially combined with radiation,
deterred many surgeons and oncologists from con-
sidering this approach.19,20 A few recent publica-
tions showed excellent and even superior survival
results for open esophagectomy after neoadjuvant
chemotherapy or CRT therapy, as reﬂected in
particular by the Chemoradiotherapy for Oesopha-
geal Cancer followed by Surgery Study (CROSS)
trial, where MIE was not performed routinely.15,21,22
There are limitations of this study that all relate to
the retrospective nature of the analysis. Patients were
not randomized and this was not an “intent to treat”
study. Nevertheless, this is a large study with accept-
able follow-up for 3HMIE in patients who were
treated with CRT, and sufﬁcient to delineate the
detailed surgical results and outcomes.
The minimally invasive approach to esophageal
surgery is becoming more common for oncologic
cases, and there is a rapid rise in the number of MIE
cases performed today.23 Most of the major studies
of MIE for cancer have proven that it is associated
with comparable surgical and oncologic results to
open operations. However, most studies to date did
not include a large number of patients who have
received both chemotherapy and radiation before
MIE surgery.
The induction CRT itself did not seem to pose
greater technical difﬁculties, or to cause more intra-
operative complications as reﬂected by similar
median operative time, similar low rate of intra-
operative complications, relatively low and compa-
rable mean EBL, and a small number of blood
products used in the perioperative period. This
ﬁnding is consistent with open esophagectomy
comparisons, suggesting that the induction therapy
does not result in additional mortality or morbidity.
The only difference between the 2 groups was found
to be the number of patients needing transfusion.
This was signiﬁcantly higher in the neoadjuvant
group, possibly associated with the lower preoper-
ative hematocrit in this group. Most of the patients
usually receive intraoperatively a large volume of
ﬂuids (colloids and crystalloids), which cause hemo-
dilution. A lower preoperative baseline HCT may
result in a lower postoperative HCT, which sets a
lower threshold for packed red blood cells trans-
fusion during and after surgery. However, among the
transfused patients, patients in the neoadjuvantic and Cardiovascular Surgery  Volume 27, Numbegroup were not administered signiﬁcantly more
packed red blood cells units than those in the
surgery-only group. Given the evidence in other
oncologic procedures that blood replacement is
associated with less favorable cancer-related survival,
our results suggest that better strategies for blood
conservation are required in this patient cohort.
Most of the patients who received preoperative
CRT demonstrated only a partial or no response,
whereas 35% showed complete response, which is
similar to the response rate reported in the CROSS
study.22 Advanced stage at presentation, bulky
tumors, or lack of complete response to induction
therapy were not contraindications for MIE in our
patients. These characteristics made the surgery
more challenging, but did not seem to affect the
postoperative complication rate.
There were no major differences between the 2
groups in terms of postoperative complications.
When compared to other reported series, the
observed complication rates postesophagectomy
were similar or better. For example, the anticipated
pulmonary and cardiac complications occurred less
frequently than the published, reported rates for
open esophagectomy and other large MIE series.23-26
The postoperative complications such as conduit
necrosis and requirement for diversion did not occur
in our cohort. The incidences of anastomotic leaks,
vocal cord paralysis, and chylothorax were equally
low in the 2 groups. The leak rate requiring surgical
intervention was 3% (N = 2) in the neoadjuvant
treatment group and 2% (N = 1) in the surgery-only
group. This incidence is lower than recently pub-
lished data of anastomotic leak after 3HMIE,23,24
supporting our hypothesis that neoadjuvant CRT
does not compromise cervical anastomosis healing.
Our overall vocal cord injury rate of 5% (N = 6) is
comparable to those in other MIE large series reports,
but is much lower than the reported rate in an open 3-
hole procedure even though the neck part of the
operation is performed in the same open way.23,27
This might be explained by a better minimally invasive
mobilization of the esophagus, which facilitates a less
traumatic passage and dissection at the neck level, as
well as by our technique of placing a Penrose drain tied
around the esophagus to guide the dissection in the
neck and avoid nerve injury.
Our data also show satisfactory and equivalent
oncologic resection between both groups, with a
very high rate of R0 resection, adequate proximal
and distal surgical margins, and an extensive lymph
node dissection. The neoadjuvant group included 6
cases of radial R1 resection. Of these 6 patients, 1
had progression of disease, 2 had no response, and 3
patients had partial response to the neoadjuvantr 2 213
THE 3-HOLE MINIMALLY INVASIVE ESOPHAGECTOMYtherapy. Positive margins were considered as less
than 1 mm, and in all of these cases wider resection
was deemed technically impossible. These results are
comparable to results published in other minimally
invasive and open esophagectomy studies.23,24
The overall 30-day mortality was 0.8%, which is,
lower compared with open and other prior MIE
series publications.23,27 No remarkable 30-day mor-
tality difference was found between the 2 groups.
The overall 90-day mortality was 3% for the whole
cohort, and similar in both treatment groups. We
believe that both 30- and 90-day mortality should be
reported in future esophagectomy studies as these
might better reﬂect intermediate-range outcomes.
Finally, the overall 5-year survival for the entire
group of 107 patients with early-stage esophageal
cancer was 62%. The overall 5-year survival for the
neoadjuvant group was 49%, which is similar to the
results of open procedures after induction therapy in
the CROSS trial.22 These data also lend support to the
claim that MIE does not jeopardize oncologic out-
comes after neoadjuvant therapy in locally advanced
disease. Pathologic stage 0 in the induction therapy214 Semingroup actually represents a more advanced disease that
was downstaged to stage 0 after completion of CRT
with an overall 5-year survival of 50%.
CONCLUSIONS
This study demonstrates that 3HMIE is a safe and
suitable oncologic procedure, appropriate for the
treatment of both early and locoregionally advanced
esophageal malignancies. Similar operative and post-
operative outcomes were found after induction
CRT as compared to surgery only. Therefore, the
3HMIE is feasible in clinically advanced disease after
induction CRT, with low mortality and acceptable
morbidity.
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